Understanding prescription medications, over-the-counter treatments, dietary supplements, teratogenic exposures, reproductive pharmacology, and the importance of balancing maternal health with fetal development.
When preparing for pregnancy, prospective parents are often encouraged to review their nutrition, reproductive health, lifestyle habits, and environmental exposures.
But one of the most important—and sometimes most complicated—areas of preconception care involves something many people use every day:
Medications and dietary supplements.
What happens when a medication necessary for someone's health may also carry risks during pregnancy?
Are over-the-counter medications safer than prescription drugs?
Can herbal products or supplements influence fetal development?
Why does the timing of exposure matter?
And how can a person make informed decisions when scientific evidence concerning medication use during pregnancy is incomplete?
These questions are especially relevant because pregnancy frequently begins before an individual realizes conception has occurred.
Some of the most important stages of embryonic development take place during the earliest weeks.
Consequently, exposure to certain medications may occur before pregnancy recognition.
However, avoiding all medications is neither practical nor medically appropriate.
Untreated diabetes, epilepsy, hypertension, asthma, autoimmune disease, and psychiatric disorders can create substantial health risks.
In some circumstances, effective treatment may be essential for both maternal and fetal well-being.
In 2008, Dunlop and colleagues published The Clinical Content of Preconception Care: The Use of Medications and Supplements Among Women of Reproductive Age in the American Journal of Obstetrics & Gynecology.
The authors emphasized three important principles.
First, prescription drugs, over-the-counter medications, and dietary supplements are widely used among reproductive-age women.
Second, some exposures can interfere with normal embryonic or fetal development.
Third, medication decisions must balance the risks of treatment against the risks of leaving an underlying medical condition uncontrolled.
Nearly two decades later, advances in reproductive pharmacology, clinical research, and medication labeling have changed how these decisions are made.
The most important lesson is that preconception medication safety is not simply about avoiding substances. It is about selecting appropriate treatments, understanding biological risks, and maintaining maternal health through informed medical planning.
1. Why Medication Review Should Begin Before Pregnancy
Many individuals take medications regularly before realizing they are pregnant.
These may include treatments for chronic medical conditions, occasional pain relievers, allergy medications, sleep aids, or nutritional supplements.
Others use medications specifically related to reproductive health, hormonal regulation, or weight management.
The original AJOG paper emphasized that preconception review creates an opportunity to identify treatments that may require adjustment before conception.
This matters because medication changes sometimes require considerable planning.
A person with epilepsy may need a carefully supervised transition to an alternative antiseizure medication.
Someone taking isotretinoin must follow specific pregnancy-prevention requirements.
A patient using certain immunosuppressive medications may need a treatment plan that maintains disease control while reducing reproductive risks.
And an individual taking a long-acting metabolic medication may need to consider the drug's elimination period.
These situations are best addressed before pregnancy whenever possible.
However, discovering an unexpected pregnancy while taking medication does not automatically mean fetal harm has occurred.
Risk depends on the actual medication, dose, timing, duration, and other circumstances.
Appropriate professional assessment is essential.
2. Understanding Teratogenicity
A teratogen is an exposure capable of interfering with normal embryonic or fetal development under particular conditions.
Certain medications are established human teratogens.
However, not every medication-related adverse outcome is a structural birth defect.
Some exposures may affect fetal growth, organ function, pregnancy maintenance, or development after birth.
The original AJOG paper emphasized that teratogenicity depends on several factors.
These include the substance involved, dose, route of administration, timing of exposure, and developmental stage.
Individual biological characteristics may also influence exposure.
For example, oral, topical, inhaled, and injectable medications can produce different patterns of systemic exposure.
Similarly, the same medication may have different effects at different stages of pregnancy.
This means that labeling a medication simply as safe or unsafe often oversimplifies the available evidence.
A more appropriate assessment asks what specific outcomes are associated with exposure, under which circumstances, and with what degree of certainty.
3. Why Timing Matters: The Critical Windows of Development
One of the most important concepts discussed in the AJOG paper is the relationship between medication exposure and developmental timing.
Early embryonic development involves rapid cellular division, differentiation, and organ formation.
The period of major organogenesis occurs approximately during weeks 5–10 of gestational age, although individual structures have different periods of vulnerability.
Exposure during organogenesis may influence structural development when the substance has relevant teratogenic properties.
However, developmental vulnerability does not disappear after organogenesis.
Later fetal exposures may affect growth, organ function, neurodevelopment, or physiological adaptation.
For example, certain medications can affect fetal kidney function during the second half of pregnancy.
Others may cause neonatal adaptation symptoms when used close to delivery.
Consequently, a medication's reproductive risk cannot be determined solely by whether exposure occurred during the first trimester.
The timing must be interpreted in relation to the particular drug and the developmental process involved.
4. Why Pregnancy Changes Medication Metabolism
Pregnancy produces substantial physiological changes that can affect how medications move through the body.
Plasma volume expands.
Cardiac output and renal blood flow increase.
Glomerular filtration changes.
Gastrointestinal motility may be altered.
Some liver enzymes become more or less active.
Changes in plasma proteins may also influence the distribution of particular medications.
These processes affect pharmacokinetics: absorption, distribution, metabolism, and elimination.
For example, increased renal clearance may reduce circulating concentrations of certain medications.
Other drugs may accumulate or require different dosing strategies because of changes in metabolism.
However, these effects are drug-specific.
It would be inappropriate to assume that all medication doses should be increased or decreased during pregnancy.
For some medications, therapeutic drug monitoring can help guide treatment.
The important principle is that pregnancy changes physiology, and medication management should account for those changes when clinically relevant.
5. The FDA Replaced the Old Pregnancy Risk Categories
The original 2008 article described the FDA's former pregnancy classification system.
Medications were assigned categories A, B, C, D, or X.
Although intended to communicate reproductive risk, the categories had important limitations.
They sometimes suggested that medications could be ranked along a simple scale from safest to most dangerous.
However, a single letter could not adequately represent differences in exposure timing, dose, study quality, or the consequences of untreated illness.
In 2014, the FDA finalized the Pregnancy and Lactation Labeling Rule, which took effect in June 2015.
The new system replaced the pregnancy letter categories in applicable prescription drug labeling.
Instead, medication labels provide narrative information about pregnancy-related risks, available data, clinical considerations, and lactation.
The labeling framework also addresses fertility and contraception considerations for people of reproductive potential.
This represents an important conceptual improvement.
A medication's clinical appropriateness cannot be determined from one letter or a generic safety label.
6. Why the Risk of Untreated Disease Must Be Considered
A common misunderstanding is that reducing medication exposure always improves pregnancy safety.
This is not necessarily true.
Some medical conditions create substantial risks when inadequately treated.
Poorly controlled diabetes can increase the risk of congenital anomalies and other pregnancy complications.
Uncontrolled epilepsy can produce serious maternal and fetal risks.
Severe hypertension can compromise cardiovascular and placental health.
Poorly controlled asthma may affect maternal oxygenation.
Untreated severe psychiatric illness can disrupt sleep, nutrition, functioning, and safety.
Consequently, discontinuing medication without a suitable alternative may worsen the overall clinical situation.
The appropriate comparison is not always medication versus no medication.
It is often effective treatment versus inadequately controlled disease, including the risks of each.
Preconception counseling should therefore evaluate both sides of the equation.
7. Antiseizure Medications: One of the Clearest Examples of Individualized Risk
Epilepsy illustrates why medication selection matters.
Certain antiseizure medications are associated with increased risks of major congenital malformations or adverse neurodevelopmental outcomes.
However, uncontrolled convulsive seizures can also be dangerous.
In 2024, the American Academy of Neurology, American Epilepsy Society, and Society for Maternal-Fetal Medicine published updated guidance concerning antiseizure medication use during pregnancy.
The guideline emphasizes maintaining effective seizure control while minimizing avoidable fetal risks.
It recommends considering medications such as lamotrigine, levetiracetam, or oxcarbazepine when appropriate for the individual's epilepsy syndrome and clinical circumstances.
The guideline also recommends avoiding valproic acid when clinically feasible because of its established reproductive and neurodevelopmental risks.
However, the optimal medication is not the same for every patient.
Treatment selection depends on seizure type, previous response, side effects, and other medical conditions.
8. What Do Newer Studies Reveal About Valproate?
Valproate is effective for certain seizure disorders and other medical conditions.
However, prenatal exposure is associated with increased risk of neural tube defects, other congenital anomalies, and certain neurodevelopmental outcomes.
A large population-based cohort study published in The BMJ in 2026 examined neurodevelopmental outcomes following prenatal exposure to different antiseizure medications.
The findings reinforced concerns involving valproate.
For several other antiseizure medications, the results were generally more reassuring, although uncertainty remains for some uncommon outcomes.
The study also identified possible signals involving certain drugs that require further investigation.
These findings demonstrate why clinical risk cannot be assumed to be identical across an entire medication class.
However, individuals taking valproate should not independently discontinue treatment because they wish to conceive.
A medically supervised transition may be necessary, and alternative therapies may not be equally effective for every condition.
9. Folic Acid and Antiseizure Medication Use
Folate supplementation is a foundational component of preconception care.
Its role becomes particularly relevant among individuals taking certain antiseizure medications.
The 2024 AAN/AES/SMFM guideline recommends at least 0.4 mg of folic acid daily before conception and during pregnancy for people treated with antiseizure medications.
However, the appropriate dose may vary according to the individual's circumstances and clinician recommendations.
Some patients may require additional folate-related counseling.
Importantly, folic acid supplementation does not eliminate all risks associated with potentially teratogenic antiseizure medications.
It should be viewed as one component of appropriate reproductive care rather than a substitute for medication review.
10. Isotretinoin: A Medication Requiring Strict Pregnancy Prevention
Isotretinoin is a systemic retinoid used to treat certain severe forms of acne.
It is a well-established human teratogen.
Exposure during pregnancy can cause serious congenital abnormalities, including abnormalities affecting craniofacial structures, the heart, and central nervous system.
Because of these risks, isotretinoin is subject to strict pregnancy-prevention requirements.
Patients must follow the applicable prescribing and risk-management protocols.
For individuals planning pregnancy, treatment must be discontinued according to the medication's established requirements.
For oral isotretinoin, pregnancy avoidance for at least one month after stopping treatment is generally required.
However, reproductive planning should be discussed with the prescribing clinician.
Patients should not assume that every topical acne treatment carries the same systemic risk as oral isotretinoin.
Conversely, products derived from vitamin A should not automatically be considered harmless.
The specific formulation, exposure route, and dose matter.
11. Methotrexate, Leflunomide, and Other Immunomodulatory Therapies
Some medications used for autoimmune or inflammatory diseases may pose substantial reproductive risks.
Methotrexate is one example.
It interferes with folate-dependent cellular processes and can cause serious fetal harm.
It is generally incompatible with pregnancy.
Leflunomide is another medication requiring specific reproductive precautions.
Because its active metabolite can remain in the body for an extended period, a drug-elimination procedure and laboratory confirmation may be necessary before attempting conception.
However, autoimmune disease itself may also require careful management.
Uncontrolled inflammatory disease can create medical risks.
Consequently, medication planning should involve the prescribing specialist.
The objective is to identify pregnancy-compatible treatment strategies while maintaining adequate disease control.
Pregnancy planning should not be interpreted as a reason to abandon necessary treatment.
12. Blood Pressure Medications and Pregnancy
Chronic hypertension is an important preconception health concern.
Some medications commonly used outside pregnancy are not appropriate during gestation.
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are particularly relevant because of established fetal risks, especially later in pregnancy.
Exposure can affect fetal kidney development and function.
Individuals taking these medications should discuss pregnancy plans with their prescribing clinicians.
When appropriate, treatment may be changed before conception.
Other antihypertensive medications have more established experience in pregnancy.
However, no single treatment is suitable for every patient.
The appropriate choice depends on blood pressure control, associated medical conditions, and individual risks.
An important objective is maintaining cardiovascular health while avoiding unnecessary fetal exposure.
13. Statins: Why the FDA Changed Its Position
The 2008 AJOG paper classified statins among medications contraindicated during pregnancy under the former FDA system.
However, regulatory guidance has evolved.
In July 2021, the FDA requested removal of its strongest pregnancy warning for statins.
The agency concluded that a universal contraindication was not appropriate because a small group of patients with very high cardiovascular risk may require ongoing treatment.
Examples include certain patients with severe familial hypercholesterolemia or established cardiovascular disease.
Nevertheless, the FDA continues to advise that most pregnant patients should discontinue statin therapy.
For most individuals, temporary discontinuation during pregnancy is unlikely to meaningfully affect long-term cardiovascular outcomes.
This does not mean that statins should routinely be continued during pregnancy.
It means that treatment decisions should account for the patient's cardiovascular risk rather than apply a blanket classification.
The distinction is particularly important for individuals with serious underlying disease.
14. Warfarin and Anticoagulant Management
Warfarin is an anticoagulant used to prevent or treat certain thromboembolic conditions.
However, fetal exposure can cause characteristic developmental abnormalities and other complications.
For many indications, alternative anticoagulant strategies are preferred during pregnancy.
Low-molecular-weight heparin is commonly used because it does not cross the placenta in the same way as warfarin.
However, anticoagulant management becomes more complex in certain conditions, including mechanical heart valves.
In these situations, the maternal risks associated with different treatments can be substantial.
A universal recommendation to replace warfarin without individualized assessment would be inappropriate.
Preconception care should involve the relevant cardiology, hematology, and maternal-fetal medicine specialists.
The objective is to develop a coordinated plan before pregnancy begins whenever possible.
15. Psychiatric Medications: Avoiding the False Choice Between Maternal and Fetal Health
Depression, anxiety, bipolar disorder, and other psychiatric conditions may require medication.
For many patients, treatment is essential for maintaining functioning and well-being.
However, concern about fetal exposure can lead individuals to consider stopping medication abruptly.
This may create substantial risks.
Certain psychiatric medications have specific reproductive considerations.
For example, valproate carries important teratogenic risks when used for bipolar disorder.
Lithium requires individualized counseling and monitoring.
Antidepressant safety varies according to the medication and clinical context.
However, psychiatric treatment should not be judged solely according to potential fetal exposure.
The consequences of recurrent depression, severe mood episodes, or untreated psychiatric illness also matter.
The appropriate approach involves collaborative planning with qualified mental health and obstetric clinicians.
When a medication has provided substantial benefit, treatment decisions should carefully consider the risks of changing it.
16. Acetaminophen: Understanding the Difference Between Association and Causation
Acetaminophen is widely used for pain and fever.
Its reproductive safety has attracted considerable research and public attention.
Some observational studies have identified associations between prenatal acetaminophen exposure and neurodevelopmental diagnoses in offspring.
However, these findings are difficult to interpret because medication use may be associated with underlying medical conditions, family characteristics, and other factors.
In 2024, a major study published in JAMA examined 2,480,797 children in Sweden.
Researchers compared conventional observational analyses with sibling-control analyses designed to account for certain shared familial factors.
Initial models identified small associations between acetaminophen exposure and autism or ADHD.
However, analyses comparing siblings did not find evidence of increased risk.
The adjusted hazard ratio for autism was 0.98, and for ADHD it was also 0.98.
The findings suggested that some previously observed associations may have reflected confounding.
Nevertheless, the broader scientific and regulatory discussion has continued.
In September 2025, the FDA announced action concerning a possible association between acetaminophen use during pregnancy and neurodevelopmental conditions, while acknowledging that causation had not been established.
ACOG challenged the interpretation of that evidence and continued to affirm acetaminophen's clinical role when needed.
The most appropriate patient message is to discuss treatment of pain or fever with a qualified clinician, use medication only as needed, and avoid treating uncertain associations as established causal effects.
17. NSAIDs: Why Gestational Timing Changes Risk
Nonsteroidal anti-inflammatory drugs, or NSAIDs, include ibuprofen, naproxen, and several other medications used to treat pain and inflammation.
These medications inhibit cyclooxygenase enzymes and influence prostaglandin production.
However, prostaglandins also participate in reproductive and fetal physiology.
In 2020, the FDA issued a safety communication recommending avoidance of NSAIDs at approximately 20 weeks of pregnancy or later unless specifically directed by a healthcare professional.
The concern involves fetal kidney dysfunction and reduced amniotic fluid.
After approximately 30 weeks, NSAIDs may also affect the fetal ductus arteriosus.
However, low-dose aspirin prescribed for certain obstetric conditions is an important exception.
For example, 81 mg aspirin may be recommended to reduce preeclampsia risk in appropriately selected patients.
Therefore, the general instruction to avoid aspirin during all pregnancy circumstances is not correct.
Dose, indication, timing, and medical supervision are essential.
18. Weight-Loss Medications and GLP-1 Receptor Agonists
The growing use of GLP-1 receptor agonists has introduced new questions into preconception care.
Medications such as semaglutide are used for specific metabolic and weight-related indications.
However, reproductive planning requires attention to medication-specific pregnancy labeling.
Current semaglutide labeling generally recommends discontinuation at least two months before planned pregnancy because of the medication's prolonged elimination period.
Recommendations for other agents may differ.
Patients should follow the prescribing information for their specific medication.
In November 2025, researchers published Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation in JAMA.
The study evaluated a large health-system cohort and compared selected pregnancies involving prior GLP-1 therapy with matched unexposed pregnancies.
Women with previous GLP-1 treatment who discontinued the medication before or during early pregnancy experienced approximately 3.3 kg greater mean gestational weight gain.
They also had higher observed rates of certain pregnancy complications.
However, the study was observational.
It does not prove that discontinuation directly caused these outcomes.
The findings highlight the importance of planning for metabolic management after medication changes rather than relying exclusively on the medication's effects before conception.
19. Why Weight-Loss Medication Discontinuation Requires a Broader Plan
Discontinuing a medication may alter appetite, weight trajectory, glucose regulation, or other metabolic characteristics.
For some individuals, these changes may be clinically important.
A preconception plan should therefore consider both medication safety and continued management of the condition being treated.
For a person with type 2 diabetes, adequate glycemic control before conception is particularly important.
For someone receiving treatment for obesity, nutrition, physical activity, and other evidence-based supports may help maintain health during the transition.
However, no lifestyle program can guarantee that medication-related physiological changes will be prevented.
The objective is to create a realistic plan with the treating clinician rather than abruptly discontinue treatment without follow-up.
20. Over-the-Counter Medications Are Still Pharmacologically Active
Many individuals assume that medications available without a prescription are inherently safer.
However, over-the-counter status does not establish pregnancy safety.
Cold and flu remedies may contain several active ingredients.
Pain relievers may include NSAIDs.
Sleep products may contain sedating antihistamines or other compounds.
Some preparations combine medications in ways that make it difficult to recognize duplicate dosing.
For example, acetaminophen appears in numerous combination products.
Taking more than one product containing acetaminophen can unintentionally increase total exposure.
Similarly, decongestants may not be appropriate for every patient, particularly those with certain cardiovascular conditions.
Preconception medication review should therefore include the actual ingredient list rather than only product names.
A pharmacist can be an important resource.
21. Herbal Medicines: Natural Does Not Automatically Mean Safe
Herbal products contain biologically active compounds.
Some may influence enzymes, receptors, coagulation, endocrine processes, or other physiological functions.
However, many botanical supplements have limited reproductive safety data.
A traditional history of use does not necessarily establish safety during pregnancy.
Similarly, evidence that a compound produces a desirable biological effect in a laboratory does not demonstrate that it is beneficial for pregnant humans.
Products may also vary in composition.
The concentration of active ingredients can differ according to extraction methods, manufacturing processes, and botanical sources.
Some preparations contain multiple herbs, creating additional uncertainty.
For prospective parents, the safest approach is to review botanical products with a qualified clinician or pharmacist before conception.
The absence of established harm should not be confused with evidence of safety.
22. Prenatal Vitamins Versus High-Dose Supplement Protocols
Certain nutritional supplements have established roles in preconception care.
Folic acid is a clear example.
Adequate intake reduces the risk of neural tube defects.
Other nutrients, including iron, iodine, vitamin B12, and vitamin D, may require attention according to diet, health history, and clinical circumstances.
However, more supplementation does not necessarily produce better outcomes.
High doses of certain nutrients can create adverse effects.
Excessive preformed vitamin A can be teratogenic.
Excessive iodine can disrupt thyroid regulation.
High-dose mineral supplementation can interfere with absorption or metabolism of other nutrients.
Similarly, combining multiple prenatal, fertility, and wellness products can result in overlapping doses.
A complete supplement review should therefore identify ingredients, quantities, and clinical purpose.
The objective is to meet nutritional requirements safely—not maximize every nutrient concentration.
23. Fertility Supplements and Hormone-Balancing Products
A growing commercial market promotes supplements for fertility, hormone balance, menstrual regularity, and reproductive optimization.
These products may contain vitamins, minerals, herbs, amino acids, or other bioactive compounds.
However, marketing language often exceeds the available clinical evidence.
A product may claim to improve egg quality, implantation, progesterone levels, or endocrine balance without demonstrating improved live-birth outcomes in well-designed trials.
Similarly, an ingredient's involvement in a biological pathway does not establish that supplementation improves reproductive function.
Products marketed as hormone balancing deserve particular caution because their mechanisms and safety profiles may be poorly characterized.
For prospective parents, supplementation should be based on established nutritional needs or a clinically justified indication.
It should not replace appropriate investigation of infertility, menstrual dysfunction, or other reproductive concerns.
24. Drug Interactions and the Importance of a Complete Medication List
One challenge in preconception care is that patients may receive prescriptions from several clinicians.
A primary care physician may manage blood pressure.
A neurologist may prescribe medication for epilepsy or migraine.
A psychiatrist may manage psychiatric treatment.
A dermatologist may prescribe acne medication.
Additional over-the-counter products or supplements may be purchased independently.
Without a complete medication history, no individual clinician may recognize the entire exposure profile.
This can create risks involving drug interactions, duplicate ingredients, or unintended combinations.
A useful preconception review should include every prescription medication, over-the-counter drug, supplement, and relevant topical preparation.
It should also document the dose, frequency, clinical indication, and prescribing clinician.
This information allows appropriate professionals to identify meaningful concerns and coordinate treatment.
25. What Happens if Someone Becomes Pregnant While Taking a Medication?
An unexpected exposure can create considerable anxiety.
However, a medication exposure during early pregnancy does not automatically mean that fetal harm has occurred.
The appropriate response depends on the medication.
Certain products, such as isotretinoin, require immediate contact with the prescribing clinician and specific risk management.
Other medications should not be stopped abruptly because doing so could create significant medical risks.
For example, sudden withdrawal of certain antiseizure medications may precipitate seizures.
Discontinuing psychiatric treatment may also create clinical concerns for selected patients.
The initial priority is to determine the exact medication, dose, timing, and duration of exposure.
Qualified clinicians can then review the available evidence and recommend appropriate next steps.
Reliable teratology information services can be particularly helpful.
Patients should avoid making major medical decisions based solely on online lists of supposedly dangerous medications.
26. Where Can Patients Find Reliable Medication Safety Information?
Medication safety information should come from qualified sources that distinguish established risk from uncertainty.
The FDA's current prescription labeling system provides information about pregnancy, lactation, and reproductive considerations.
MotherToBaby, a service of the Organization of Teratology Information Specialists, provides patient-oriented fact sheets concerning medications and other exposures.
The National Library of Medicine's LactMed resource provides information relevant to medication use during breastfeeding.
Professional guidelines from organizations such as ACOG, the American Academy of Neurology, and relevant specialty societies can provide additional context.
However, these resources should support—not replace—individualized consultation.
A medication that is appropriate for one patient may be inappropriate for another because of the underlying condition, dose, timing, or available alternatives.
27. Why More Pharmacogenomic Testing Is Not Always Better
Genetic differences can influence medication metabolism and response.
This is the focus of pharmacogenomics.
Certain genetic variants affect drug-metabolizing enzymes, transport proteins, or other relevant biological pathways.
In some circumstances, pharmacogenomic testing can guide medication selection or dosing.
However, the presence of genetic variation does not automatically establish pregnancy-related medication risk.
A test that predicts how quickly someone metabolizes a medication may not predict whether fetal exposure will cause a particular developmental outcome.
Likewise, broad commercial pharmacogenomic panels should not be assumed to determine the safest pregnancy medication for every individual.
Clinical utility depends on whether the specific gene–drug relationship is validated and relevant to the treatment decision.
The most appropriate testing strategy begins with the clinical question rather than the availability of a comprehensive panel.
28. A Practical Preconception Medication Review
A comprehensive assessment can include several important questions.
What medications are currently being used? Include all prescriptions, over-the-counter medications, supplements, and topical products.
Why is each medication prescribed? Understand the underlying condition and the consequences of inadequate treatment.
Does the medication carry established reproductive risks? Review current drug-specific evidence rather than outdated letter categories.
Would an alternative treatment be appropriate? Consider efficacy, disease stability, and available reproductive safety data.
Is a medication transition necessary before conception? Some treatments require advance planning or specific discontinuation intervals.
Are laboratory measurements or monitoring needed? Certain medications require therapeutic monitoring or condition-specific evaluation.
Could supplementation create additional risks? Review duplicate nutrients, herbal ingredients, and interactions.
What if pregnancy occurs unexpectedly? Establish an appropriate plan for contacting the prescribing clinician.
Who should coordinate decisions? Identify relevant primary care, obstetric, and specialty clinicians.
Does the patient understand the available options? Support informed decision-making without creating unnecessary fear.
The purpose is not to eliminate every medication.
It is to create an effective, coordinated treatment plan appropriate for the patient's reproductive goals.
29. Practical Steps Before Pregnancy
Prospective parents can begin with several reasonable actions.
Prepare a complete list of current medications and supplements, including doses and frequency.
Review chronic medical conditions with the relevant prescribing clinicians before attempting conception.
Identify medications requiring specific pregnancy-prevention measures or discontinuation planning.
Discuss safer alternatives when clinically appropriate, without assuming that untreated disease is preferable.
Follow established folic acid recommendations and review the composition of prenatal supplements.
Avoid starting new herbal, fertility, or hormone-related supplements without appropriate evaluation.
Review common over-the-counter medications, particularly combination pain, cold, allergy, and sleep products.
Discuss pregnancy planning when using medications for weight management or metabolic disease.
Establish a plan for unexpected pregnancy recognition while taking prescription treatment.
Use authoritative medication safety resources and qualified professionals rather than relying on simplified online safety rankings.
These steps can support reproductive preparation without compromising necessary care.
30. How This Research Informs Our Preconception Care
We recognize that medication and supplement use is an important component of comprehensive preconception wellness.
Within our women's health, conscious conception, functional medicine, and Eat Well services, we emphasize understanding the complete clinical context surrounding a patient's treatment.
This includes relevant medical history, nutritional intake, supplement use, and lifestyle factors.
Our approach prioritizes research-informed education and appropriate coordination with prescribing clinicians.
For example, a patient taking multiple nutritional supplements may benefit from reviewing overlapping ingredients and the evidence supporting their use.
Someone with metabolic concerns may require coordinated care to maintain health while planning changes to a weight-management medication.
A patient with epilepsy, autoimmune disease, or another chronic condition may need specialist consultation well before conception.
However, decisions involving prescription medication initiation, discontinuation, substitution, or dosing must be made by appropriately qualified prescribing professionals.
We do not present dietary supplements or lifestyle interventions as replacements for necessary medical treatment.
We also recognize that advanced laboratory testing should be selected according to clinical usefulness rather than the number of biomarkers available.
The objective is to help patients understand their health, identify relevant questions, and collaborate effectively with their healthcare teams.
A personalized approach should protect both reproductive health and the ongoing medical needs of the individual preparing for pregnancy.
Conclusion: Medication Safety Requires Better Decisions, Not Simply Fewer Medications
Prescription medications, over-the-counter products, and dietary supplements are part of everyday healthcare.
For individuals planning pregnancy, their use deserves careful consideration.
Some medications carry established risks to embryonic or fetal development.
Others are essential for managing conditions that can themselves threaten maternal or fetal health.
The original 2008 AJOG paper recognized this balance.
Since its publication, regulatory changes and clinical research have improved the tools available for evaluating medication-related risks.
The FDA replaced its simplified pregnancy letter categories.
New evidence has informed the selection of antiseizure medications.
Updated research has clarified the risks of certain pain relievers.
And the growing use of metabolic medications has created new considerations for conception timing and treatment transitions.
However, important uncertainty remains.
Not every medication has been studied adequately during pregnancy.
Animal studies do not always predict human outcomes.
Observational associations can be influenced by the underlying condition being treated.
And a medication's risk may change according to dose, timing, or route of administration.
These realities support careful, individualized judgment.
The goal of preconception medication review is not to stop every medication or replace conventional treatment with supplements. It is to preserve maternal health, reduce preventable reproductive risks, and establish the safest effective treatment strategy supported by current evidence.
Because preparing for pregnancy involves protecting the health of the person who will carry it—not simply minimizing the number of substances they encounter.
Research References
Dunlop AL, Gardiner PM, Shellhaas CS, Menard MK, McDiarmid MA. The clinical content of preconception care: the use of medications and supplements among women of reproductive age. American Journal of Obstetrics and Gynecology. 2008;199(6 Suppl 2)–S372. https://doi.org/10.1016/j.ajog.2008.07.065
U.S. Food and Drug Administration. Pregnancy and Lactation Labeling Final Rule. 2014; effective June 2015. https://www.fda.gov/vaccines-blood-biologics/biologics-rules/pregnancy-and-lactation-labeling-final-rule
Pack AM, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to antiseizure medication: practice guideline from the AAN, AES, and SMFM. Neurology. 2024. https://pubmed.ncbi.nlm.nih.gov/38748979/
Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study. BMJ. 2026;392. https://www.bmj.com/content/392/bmj-2025-085725
Ahlqvist VH, Sjöqvist H, Dalman C, et al. Acetaminophen use during pregnancy and children's risk of autism, ADHD, and intellectual disability. JAMA. 2024;331(14):1205–1214. https://doi.org/10.1001/jama.2024.3172
U.S. Food and Drug Administration. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic
U.S. Food and Drug Administration. FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy. 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy
Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation. JAMA. 2025;334(24):2186–2196. https://doi.org/10.1001/jama.2025.20951
U.S. National Library of Medicine. WEGOVY (semaglutide): Prescribing Information. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
MotherToBaby. Pregnancy and Breastfeeding Exposure Fact Sheets. https://mothertobaby.org/fact-sheets/
MotherToBaby. Isotretinoin (Accutane). 2026. https://www.ncbi.nlm.nih.gov/books/NBK582775/
American College of Obstetricians and Gynecologists. Prepregnancy Counseling. Committee Opinion No. 762. 2019. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/01/prepregnancy-counseling
U.S. Food and Drug Administration. FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy. 2025. https://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy
American College of Obstetricians and Gynecologists. ACOG Affirms Safety and Benefits of Acetaminophen During Pregnancy. 2025. https://www.acog.org/news/news-releases/2025/09/acog-affirms-safety-benefits-acetaminophen-pregnancy